^
Association details:
| Biomarker: | AXL overexpression + PD-L1 expression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade
Published date:
08/18/2021
Excerpt:
In this study, tumoral expression of AXL was examined in ccRCC specimens from 316 metastatic patients receiving PD-1 inhibitor, nivolumab, in the GETUG AFU 26 NIVOREN trial after failure of anti-angiogenic therapy….patients with tumors displaying concomitant PD-L1 expression and high AXL expression had the worst overall survival.
DOI:
10.1158/1078-0432.CCR-21-0972
Trial ID:
